Aliri Videos
-
Early-Phase Whole-Body PK
4/21/2025
Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.
-
Label-Free Whole-Body Pharmacokinetics
4/21/2025
This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.
-
What Is Causing Limited Bioavailability
4/21/2025
Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.
-
Optimal Tech For Predicting Drug Responses At The Cellular Level
4/1/2025
Explore how preserving spatial molecular information and leveraging AI-driven spatial-omics can transform treatment prediction, patient stratification, and personalized medicine.
-
LC/MS Method For Measurement In Human Plasma
2/17/2025
According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.
-
LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma
2/17/2025
This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.
-
Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup
2/17/2025
By leveraging this innovative combination, the assay achieves detection limits comparable to traditional methodologies while enhancing overall efficiency and reliability.
-
Antisense Oligonucleotide Extraction Optimization Reveals Differences
2/17/2025
Our findings provide critical insights into refining ASO extraction protocols, which can enhance the accuracy of downstream analyses and support further research into ASO-based therapeutics.
-
Tissue Adenosine Distribution-Guided Gene Selection
2/17/2025
Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.
-
Webinar Teaser: LBA Vs. LC-MS
2/6/2025
Why are so many sponsors shifting from Ligand-Binding Assays (LBA) to Liquid Chromatography-Mass Spectrometry (LC-MS) for large molecule protein analysis?